86 related articles for article (PubMed ID: 38573347)
41. Resistance to Checkpoint Inhibition in Cancer Immunotherapy.
Barrueto L; Caminero F; Cash L; Makris C; Lamichhane P; Deshmukh RR
Transl Oncol; 2020 Mar; 13(3):100738. PubMed ID: 32114384
[TBL] [Abstract][Full Text] [Related]
42. Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma.
Bennani-Baiti N; Thanarajasingam G; Ansell S
Expert Rev Clin Immunol; 2016 Jun; 12(6):673-9. PubMed ID: 26818843
[TBL] [Abstract][Full Text] [Related]
43. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
[TBL] [Abstract][Full Text] [Related]
44. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
[TBL] [Abstract][Full Text] [Related]
45. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
46. Turning enemies into allies-reprogramming tumor-associated macrophages for cancer therapy.
Molgora M; Colonna M
Med; 2021 Jun; 2(6):666-681. PubMed ID: 34189494
[TBL] [Abstract][Full Text] [Related]
47. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
[TBL] [Abstract][Full Text] [Related]
48. Deciphering the potential roles of ferroptosis in regulating tumor immunity and tumor immunotherapy.
Gu X; Liu Y; Dai X; Yang YG; Zhang X
Front Immunol; 2023; 14():1137107. PubMed ID: 36926345
[TBL] [Abstract][Full Text] [Related]
49. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
50. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer.
Alemohammad H; Najafzadeh B; Asadzadeh Z; Baghbanzadeh A; Ghorbaninezhad F; Najafzadeh A; Safarpour H; Bernardini R; Brunetti O; Sonnessa M; Fasano R; Silvestris N; Baradaran B
Biomed Pharmacother; 2022 Feb; 146():112516. PubMed ID: 34906767
[TBL] [Abstract][Full Text] [Related]
51. Immune checkpoint inhibitors: review of the existing evidence and challenges in breast cancer.
Jalalvand M; Darbeheshti F; Rezaei N
Immunotherapy; 2021 May; 13(7):587-603. PubMed ID: 33775102
[TBL] [Abstract][Full Text] [Related]
52. Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma.
Petrova V; Arkhypov I; Weber R; Groth C; Altevogt P; Utikal J; Umansky V
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32235439
[TBL] [Abstract][Full Text] [Related]
53. Exosomes carrying immune checkpoints, a promising therapeutic approach in cancer treatment.
Rasihashemi SZ; Sahrai H; Rezazadeh-Gavgani E; Yazdani Y; Khalaji A; Lotfinejad P
Med Oncol; 2022 Sep; 39(12):183. PubMed ID: 36071295
[TBL] [Abstract][Full Text] [Related]
54. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
55. A novel strategy to fuel cancer immunotherapy: targeting glucose metabolism to remodel the tumor microenvironment.
Liu X; Zhao Y; Wu X; Liu Z; Liu X
Front Oncol; 2022; 12():931104. PubMed ID: 35924168
[TBL] [Abstract][Full Text] [Related]
56. Microparticle Phosphatidylserine Mediates Coagulation: Involvement in Tumor Progression and Metastasis.
Jing H; Wu X; Xiang M; Wang C; Novakovic VA; Shi J
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046617
[TBL] [Abstract][Full Text] [Related]
57. Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200.
Moon SY; Han M; Ryu G; Shin SA; Lee JH; Lee CS
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894750
[TBL] [Abstract][Full Text] [Related]
58. Extracellular Vesicles in Oncology: from Immune Suppression to Immunotherapy.
Srivastava A; Rathore S; Munshi A; Ramesh R
AAPS J; 2021 Feb; 23(2):30. PubMed ID: 33586060
[TBL] [Abstract][Full Text] [Related]
59. Role of cell surface proteoglycans in cancer immunotherapy.
Espinoza-Sánchez NA; Götte M
Semin Cancer Biol; 2020 May; 62():48-67. PubMed ID: 31336150
[TBL] [Abstract][Full Text] [Related]
60. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
Gao A; Sun Y; Peng G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
